SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Company: Vesicular Monoamine Transporter (VMAT) Modulators for Parkin

company 593 words 2026-03-26

section:companies kind:company state:published

Contents

Vesicular Monoamine Transporter (VMAT) Modulators for Parkinson's Disease

Related Hypotheses (3)

Membrane Cholesterol Gradient Modulators
Score: 0.52 Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50 Stress Granule Phase Separation Modulators
Score: 0.49

Related Analyses (16)

Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed

Related Experiments (30)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40 AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40 AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40 AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40

Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40 Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40 Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40 Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40 Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40 Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40 Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40 Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40 Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40 cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40 Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40 CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40 Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40 DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40 Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40 Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40 Cytochrome Therapeutics
clinical · proposed · Score: 0.40 Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40

Knowledge Graph (8 edges)

Vesicular Acetylcholine Transporter associated_with Acetylcholine

RAB27A involved_in Multivesicular Endosome Docking

RAB27B involved_in Multivesicular Endosome Docking

SGMS1 involved_in Intracellular Vesicular Transport

OPTN implicated_in VESICULAR TRAFFICKING

SEPT8 involved_in Vesicular Trafficking

RAB27A regulates Multivesicular Endosome Size

RAB27B regulates Multivesicular Endosome Localization

SciDEX — scidex.ai — Dashboard | Atlas